BCRX
insider transactionsBIOCRYST PHARMACEUTICALS INC — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
No open-market buys or sells this period. The trades below are grants, option exercises and gifts, which carry no market price.
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Director
$0
33.5K sh
Own New
-
Grant·A
Director
$0
15.3K sh
Own +92%
-
Grant·A
Director
$0
33.5K sh
Own New
-
Grant·A
Director
$0
15.3K sh
Own +122%
-
Grant·A
Director
$0
33.5K sh
Own New
-
Grant·A
Director
$0
15.3K sh
Own +24%
-
Grant·A
Director
$0
33.5K sh
Own New
-
Grant·A
Director
$0
15.3K sh
Own +76%
-
Grant·A
Director
$0
33.5K sh
Own New
-
Grant·A
Director
$0
15.3K sh
Own +50%
-
Grant·A
Director
$0
33.5K sh
Own New
-
Grant·A
Director
$0
15.3K sh
Own +16%
-
Grant·A
Director
$0
33.5K sh
Own New
-
Grant·A
Director
$0
15.3K sh
Own +1%
-
Grant·A
Director
$0
33.5K sh
Own New
-
Grant·A
Director
$0
15.3K sh
Own +48%
-
Grant·A
Director
$0
33.5K sh
Own New
-
Grant·A
Director
$0
15.3K sh
Own +23%
-
Grant·A
Director
$11.2K
1.3K sh · $8.91
Own +8%
-
Grant·A
Director
$5.6K
631 sh · $8.91
Own +0%
-
Grant·A
Director
$5.6K
631 sh · $8.91
Own +2%
-
Grant·A
Director
$10.0K
1.1K sh · $8.91
Own +1%
-
Grant·A
Director
$11.2K
1.3K sh · $8.91
Own +7%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 11, 2026 | Jill C. Milne | Grant A | 33.5K | $0 |
| Jun 11, 2026 | Jill C. Milne | Grant A | 15.3K | $0 |
| Jun 11, 2026 | Steven K Galson | Grant A | 33.5K | $0 |
| Jun 11, 2026 | Steven K Galson | Grant A | 15.3K | $0 |
| Jun 11, 2026 | Alan G Levin | Grant A | 33.5K | $0 |
| Jun 11, 2026 | Alan G Levin | Grant A | 15.3K | $0 |
| Jun 11, 2026 | Steven Frank | Grant A | 33.5K | $0 |
| Jun 11, 2026 | Steven Frank | Grant A | 15.3K | $0 |
| Jun 11, 2026 | Machelle Sanders | Grant A | 33.5K | $0 |
| Jun 11, 2026 | Machelle Sanders | Grant A | 15.3K | $0 |
| Jun 11, 2026 | Vincent Milano | Grant A | 33.5K | $0 |
| Jun 11, 2026 | Vincent Milano | Grant A | 15.3K | $0 |
| Jun 11, 2026 | Jon P Stonehouse | Grant A | 33.5K | $0 |
| Jun 11, 2026 | Jon P Stonehouse | Grant A | 15.3K | $0 |
| Jun 11, 2026 | Amy E Mckee | Grant A | 33.5K | $0 |
| Jun 11, 2026 | Amy E Mckee | Grant A | 15.3K | $0 |
| Jun 11, 2026 | Theresa Heggie | Grant A | 33.5K | $0 |
| Jun 11, 2026 | Theresa Heggie | Grant A | 15.3K | $0 |
| May 29, 2026 | Jill C. Milne | Grant A | 1.3K | $11.2K |
| May 29, 2026 | Jon P Stonehouse | Grant A | 631 | $5.6K |
| May 29, 2026 | Amy E Mckee | Grant A | 631 | $5.6K |
| May 29, 2026 | Vincent Milano | Grant A | 1.1K | $10.0K |
| May 29, 2026 | Steven Frank | Grant A | 1.3K | $11.2K |
About BCRX insider trading
This page tracks insider transactions for BIOCRYST PHARMACEUTICALS INC (BCRX) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.